GluBio’s Novel Oral Molecular Glue Degrader GLB-002 Combined with Rituximab Secures Phase II Clinical Trial Approval
April 28, 2026
Shanghai, China & San Diego, USA, April 28, 2026 — GluBio Therapeutics today announced that the National Medical Products Administration(NMPA) of China has approved its Phase II clinical trial application for GLB-002 in combination with rituximab.
As a next-generation selective molecular glue degrader targeting IKZF1 and IKZF3, GLB-002 will be evaluated in patients with relapsed/refractory follicular lymphoma (R/R FL). This milestone comes after GLB-002 obtained its first clinical approval in September 2023, marking the official entry of the candidate into Phase II clinical research.
Follicular lymphoma (FL) is a common subtype of indolent non-Hodgkin lymphoma (NHL) in clinical practice. Although anti-CD20 monoclonal antibody-based chemoimmunotherapy has benefited FL patients, many still face disease progression and drug resistance. For those with relapsed/refractory FL, effective treatment options remain limited. In recent years, several small-molecule drugs targeting alternative pathways previously approved for R/R FL have been withdrawn from the market due to safety concerns-highlighting a substantial unmet medical need in this field.
At the 2025 ASH Annual Meeting, GluBio released Phase I clinical data of GLB-002. The results confirmed that GLB-002 delivers a high response rate and durable efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL), Robust clinical benefits were observed in follicular lymphoma and marginal zone lymphoma (MZL) populations, with a favorable and manageable safety profile.
Supported by these promising data, GluBio is accelerating the clinical development and pipeline expansion of GLB-002 across NHL indications. The company strives to establish a leading position in this field and deliver superior treatment options for NHL patients-including those with R/R FL -at the earliest opportunity.
April 28, 2026